“Largest study to date on real-world safety and effectiveness…

of any type of ketamine treatment and specifically for sublingual, at-home administration of ketamine-assisted therapy (KAT)”

2023-04-18 8:52 MST

At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial

This is the most extensive study on real-world safety and effectiveness of any ketamine treatment, specifically for sublingual, at-home administration of ketamine-assisted therapy (KAT) for depression and anxiety. From a chart review of 4334 cases, 1247 individuals had sufficient data to evaluate baseline characteristics, adverse events, dissociation, and clinical outcomes. These data suggested that KAT offered clinically meaningful improvement and demonstrated a desirable safety and risk mitigation profile.

Baseline PHQ-9 scores suggested that this sample was predominantly in the moderately-severe category for depression, and baseline GAD-7 scores suggested participants were predominantly in the severe category for anxiety. These baseline means are two to three points lower than those reported for depression in ketamine lab studies (Fava et al., 2020; Phillips et al., 2019) and in a real-world effectiveness study (McIn)